Instituto de Investigaciones en Reproducción, Universidad de Buenos Aires, Buenos Aires, Argentina.
Am J Physiol Endocrinol Metab. 2012 Feb 1;302(3):E356-64. doi: 10.1152/ajpendo.00333.2011. Epub 2011 Nov 15.
Since anterior pituitary expresses prolactin receptors, prolactin secreted by lactotropes could exert autocrine or paracrine actions on anterior pituitary cells. In fact, it has been observed that prolactin inhibits its own expression by lactotropes. Our hypothesis is that prolactin participates in the control of anterior pituitary cell turnover. In the present study, we explored the action of prolactin on proliferation and apoptosis of anterior pituitary cells and its effect on the expression of the prolactin receptor. To determine the activity of endogenous prolactin, we evaluated the effect of the competitive prolactin receptor antagonist Δ1-9-G129R-hPRL in vivo, using transgenic mice that constitutively and systemically express this antagonist. The weight of the pituitary gland and the anterior pituitary proliferation index, determined by BrdU incorporation, were higher in transgenic mice expressing the antagonist than in wild-type littermates. In addition, blockade of prolactin receptor in vitro by Δ1-9-G129R-hPRL increased proliferation and inhibited apoptosis of somatolactotrope GH3 cells and of primary cultures of male rat anterior pituitary cells, including lactotropes. These results suggest that prolactin acts as an autocrine/paracrine antiproliferative and proapoptotic factor in the anterior pituitary gland. In addition, anterior pituitary expression of the long isoform of the prolactin receptor, measured by real-time PCR, increased about 10-fold in transgenic mice expressing the prolactin receptor antagonist, whereas only a modest increase in the S3 short-isoform expression was observed. These results suggest that endogenous prolactin may regulate its own biological actions in the anterior pituitary by inhibiting the expression of the long isoform of the prolactin receptor. In conclusion, our observations suggest that prolactin is involved in the maintenance of physiological cell renewal in the anterior pituitary. Alterations in this physiological role of prolactin could contribute to pituitary tumor development.
由于垂体前叶表达催乳素受体,催乳素可以通过催乳素细胞发挥自分泌或旁分泌作用。事实上,已经观察到催乳素抑制其自身的表达。我们的假设是,催乳素参与了垂体前叶细胞更新的控制。在本研究中,我们探讨了催乳素对垂体前叶细胞增殖和凋亡的作用及其对催乳素受体表达的影响。为了确定内源性催乳素的活性,我们评估了竞争催乳素受体拮抗剂 Δ1-9-G129R-hPRL 在体内的作用,使用持续和系统表达这种拮抗剂的转基因小鼠。表达拮抗剂的转基因小鼠的垂体重量和通过 BrdU 掺入测定的垂体前叶增殖指数高于野生型同窝小鼠。此外,体外通过 Δ1-9-G129R-hPRL 阻断催乳素受体增加了 GH3 细胞和雄性大鼠垂体前叶细胞原代培养物(包括催乳素细胞)的增殖并抑制了凋亡。这些结果表明,催乳素在垂体前叶中作为自分泌/旁分泌抗增殖和促凋亡因子发挥作用。此外,通过实时 PCR 测量,在表达催乳素受体拮抗剂的转基因小鼠中,长型催乳素受体的表达增加了约 10 倍,而短型 S3 表达仅略有增加。这些结果表明,内源性催乳素可能通过抑制长型催乳素受体的表达来调节其在垂体前叶中的自身生物学作用。总之,我们的观察结果表明,催乳素参与了垂体前叶生理细胞更新的维持。这种催乳素生理作用的改变可能导致垂体瘤的发展。